Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Lung Cancer
Interventions
DRUG

docetaxel

DRUG

irinotecan hydrochloride

Trial Locations (19)

55416

CCOP - Metro-Minnesota, Saint Louis Park

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

CentraCare Clinic, Saint Cloud

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

58201

Altru Health Systems, Grand Forks

58501

Quain & Ramstad Clinic, P.C., Bismarck

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68131

CCOP - Missouri Valley Cancer Consortium, Omaha

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

43623-3456

CCOP - Toledo Community Hospital Oncology Program, Toledo

57105-1080

CCOP - Sioux Community Cancer Consortium, Sioux Falls

S4S 6X3

Saskatchewan Cancer Agency, Regina

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00003900 - Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter